Proactive Investors
07 Aug 2026, 08:07 UTC · 2h ago
Oxford BioMedica tanks 24% after earnings alert; brokers take stock
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
07 Aug 2026, 08:07 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Oxford BioMedica PLC (OXB) cut its 2026 EBITDA guidance to approximately £9.5 million, representing a roughly 50% reduction compared to analyst consensus of £21.9 million. — A massive earnings miss of this magnitude typically triggers significant valuation resets and immediate share price depreciation.
-0.80Oxford BioMedica revised its 2026 revenue guidance downward to a range of £180 million to £200 million from a previous range of £220 million to £240 million. — The revenue downgrade confirms a slowdown in growth and reflects negative shifts in client ordering behavior and procurement strategies.
-0.50The company experienced a six-month delay in integrating its Durham, North Carolina site, though it claims the facility is now operational. — Execution delays in expanding capacity suggest operational friction, though the 'back on track' status mitigates some risk.
-0.30Continue reading
6 related stories
Top 3 movers · tap to explore
The company reports a revenue backlog of approximately £193 million, with 87% of this year's new midpoint revenue range already covered by contracts. — High visibility of future revenue provides a floor for the stock and supports the 'Buy' ratings maintained by brokers.
+0.30Oxford BioMedica maintained its medium-term targets, including 25% to 30% revenue growth in 2027 and £500 million in revenue by 2030. — Maintaining long-term targets provides a bullish counter-narrative to the short-term miss, though investors may view this as overly optimistic given the current downgrade.
+0.20Which stocks this story touches
The company's shares fell 19% following a significant cut to 2026 earnings guidance and a revenue downgrade.
The company is mentioned in the context of an interview with its chair, but no material financial news or sentiment is provided.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
23m ago
